← Search & browse all drugs
VARIOUS › DIAGNOSTIC AGENTS › OTHER DIAGNOSTIC AGENTS › Tests for pituitary function
macimorelin
V04CD06
Forms & Strengths
- Oral tablet 0.5 mg (single‑dose formulation)
Adult Dosing
- Single oral dose 0.5 mg/kg (max 50 mg) after overnight fast
- Blood samples for GH at baseline, 30, 45, 60 and 90 min
Pediatric Dosing
- Not approved; safety and efficacy not established in children
Indications
- Diagnostic GH stimulation test to evaluate adult growth‑hormone deficiency
Mechanism of Action
- Synthetic ghrelin (GHSR‑1a) receptor agonist
- Stimulates pituitary somatotrophs → rapid GH release
- Secondary rise in cortisol and IGF‑1
Contraindications
- Known hypersensitivity to macimorelin or excipients
- Active malignancy or pheochromocytoma
- Severe uncontrolled diabetes or hyperglycemia
Adverse Reactions
- Nausea, vomiting or abdominal discomfort
- Headache, dizziness or flushing
- Transient hyperglycemia
- Taste alteration or dysgeusia
Drug Interactions
- CYP3A4 inhibitors (e.g., ketoconazole) may increase exposure
- CYP3A4 inducers (e.g., rifampin) may reduce effect
- Somatostatin analogs (octreotide) blunt GH response
- Caution with insulin or oral hypoglycemics due to hyperglycemia
Curated Content: Needs Vetting Before Put to Clinical Use